Altered Trajectories: Blue Hen Chemist to Biotech Entrepreneur
Stephen Betz, Founder & VP Biology, of Crinetics Pharmaceuticals
Dr. Betz is the Vice-President of Biology and a founder of Crinetics Pharmaceuticals. Prior to Crinetics, he was director of endocrinology and metabolism at Neurocrine Biosciences and worked on the discovery and development of GnRH receptor antagonists and nonpeptide modulators of other endocrine targets. This work led to the discovery and development of the GnRH antagonist, elagolix, which has shown robust efficacy in relieving symptoms associated with endometriosis and uterine
fibroids. Prior to Neurocrine, he led laboratory efforts at GeneFormatics, and at Abbott Laboratories worked in pharmaceutical discovery, including structure-guided drug design, assay development, and compound screening in the Research NMR Group. He holds a B.S. in chemistry from the University of Delaware and Ph.D. in chemistry from the University of North Carolina at Chapel Hill.